by bone marrow derived macrophages, and was specific for the stem cell compartment, having no inhibitory effects on more mature progenitors.
We have recently developed an in vitro assay for a cell with properties in common with the day 12 CFU-S cell (Pragnell et al., 1988; Lorimore et al., 1990) . This assay has been used to characterise and purify an inhibitor of CFU-S proliferation ) which we have called Stem Cell Inhibitor (SCI) .
Primary sequence analysis revealed that murine SCI is identical to a previously described cytokine, Macrophage Inflammatory Protein lx (Davatelis et al., 1988) , a member of a large family of related cytokines. This family is defined on the basis of sequence homology and on the presence of four cysteines which have been positionally conserved (for a review see Wolpe & Cerami, 1989) . A subset within this family includes the basic cytokine MIP-2, (PF-4), P-thromboglobulin, Interleukin-8 and melanoma growth stimulatory activity (MGSA) proteins. MIP-2 and PF4 are chemotactic for polymorphonuclear cells (see Wolpe & Cerami, 1989) .
SCI/MIP-la is a small heparin binding peptide with a molecular weight of 8 kD although the molecule readily forms large non covalent aggregates with molecular weights in excess of one million daltons. Intriguingly, a related peptide (70% homologous at the amino acid level), MIP-1lB (Wolpe & Cerami, 1989) , which copurified with MIP-lo displays no inhibitory activity at the concentrations tested . More recent reports suggest that SCI/MIP-la, MIP-1p and MIP-2 can stimulate progenitor cell proliferation, but only in conditions where growth factor concentrations are limiting in in vitro progenitor assays (Broxmeyer et al., 1990) .
The human SCI/MIP-lo homologue is also a peptide with a molecular weight of approximately 8 kD and forms large self aggregates. It is equally effective as a CFU-S proliferation inhibitor and we are currently using the human SCI/ MIP-lo in preclinical trials designed to test its efficacy in reducing myelotoxicity during drug treatment of mice.
The inhibitory activities of SCI/MIP-lx are not confined to the haemopoietic system. We have shown both human and murine SCI/MIP-Ia to be active in inhibiting clonogenic epidermal cells (Parkinson & Graham, unpublished results) , although it is not yet clear whether this is a direct or indirect effect on the primary epidermal cells. The source of SCI/ MIP-1x in vivo in the skin remains to be determined, however, two possibilities are being considered. In the normal mouse skin epidermal proliferation unit (EPU), a Langerhans cell, which is of monocytic/lymphoid origin and expresses SCI/MIP-la, is in close proximity to the slow cycling epidermal keratinocyte and may be involved in establishing the proliferative hierarchy observed. Alternatively, during skin wounding and/or inflammation, local infiltration of macrophages and T-cells may produce SCI/MIP-1o although the functional implications of such production would have to be investigated. The availability of probes allowing in situ or immunocytochemical analysis should allow us to investigate these possibilities further.
SCI/MIP-la gene structure The mouse MIP-loa protein was originally purified from endotoxin stimulated macrophages and sequenced. This led to the isolation of a cDNA alone (Davatelis et al., 1988) and subsequent isolation and sequence of a single encoding gene (Grove et al., 1990 (Xu et al., 1990) ; and (c) a loss of heterozygosity (LOH) in breast cancer (Cropp et al., 1990) . Although it is unlikely that the SCI/MIP-la gene is itself directly involved in the cellular transformation process, nearby genetic lesions which activate proto-oncogenes or inactive suppressor genes may also coincidentally lead to aberrant SCI/MIP-la gene expression. The up-regulation of SCI/MIP-Ia gene expression has been detected in the peripheral blood of a number of ANLL and ALL patients (Yamamura et al., 1989) (Lord & Wright, 1980) and monocytes (Pojda et (Yamamura et al., 1989) and mast cells (Gordon et al., 1990 (Davatelis et al., 1988) and human (Forsdyke, 1985; Obaru et al., 1986; Zipfel et al., 1989) SCI/MIP-lI cDNAs revealed a number of conserved (TATTT) motifs in the 3' untranslated region of the mRNA which have been implicated in the modulation of mRNA stability of a number of other cytokine mRNAs (Caput et al., 1986; Shaw & Kamen, 1986) . Similarly, as mentioned above, SCI/MIP-lI mRNA is super-induced during endotoxin (lipopolysacharride, LPS) stimulation of murine macrophages (Davatelis et al., 1988) , and is super-induced in human T-cell lines by phorbol esters (PMA) and/or PHA and cyclohexamide (Obaru et al., 1986; Yamamura et al., 1989; Blum et al., 1990 ). Interestingly, a basal level of SCI/MIP-lac mRNA is detected in unstimulated cultured murine macrophage Davatelis et al., 1988) and mast cell lines (Gordon et al., 1990, and M.P. unpublished results), whereas it is undetectable in unstimulated human monocyte (U937) and T-cell (Jurkat) lines although it can be induced by PHA and/or PMA (Obaru et al., 1986; Yamamura et al., 1989; Blum et al., 1990) .
Sequence comparison of the proximal promoters of the human and mouse SCI/MIP-lac genes with those of other cytokine genes such as GM-CSF, have revealed a number of conserved potential transcription factor binding sites. These include potential NF-icB (related to the c-Rel proto-oncogene (Ballard et al., 1990) ), NF-GMa (which may be related to the NF-KB family of proteins, (Shannon et al., 1990) ), API (encoded by the c-fos and c-jun proto-oncogenes, for review see Abate & Curran, 1990 ) and PU1 (a member of the c-ets family of proto-oncogenes (Klemsz et al., 1990) ) binding sites. These transcription factors are all nuclear proto-oncogenes which have been implicated in the early response to mitogenic stimulii (e.g. phorbol esters and AP1) and in cell proliferation. This implies that SCI-MIP-la gene transcription is regulated as a function of cell proliferation/activation, and as it is a negative regulator of stem cell proliferation it is tempting to speculate that one role of SCI/MIP-ia, particularly that produced by macrophages in the bone marrow, is as a classical negative feedback factor. Furthermore, it raises the possibility that the activation of the nuclear protooncogene(s) in certain neoplasias may lead to aberrant SCI/ MIP-hi gene expression.
Concluding remarks
It is clear that SCI/MIP-la gene expression is specific to a limited number of haemopoietic cells, is regulated at both transcriptional and post-transcriptional levels, and may also be regulated at the translational and post-translational levels.
There is ample evidence to suggest that the control of haemopoietic stem cell proliferation occurs at the level of the stromal micro-environment. It is therefore necessary to examine the localisation of SCI/MIP-la protein in the bone marrow extra-ellular matrix as it is clearly synthesised and released by normal bone marrow cells, including macrophages. One obvious approach is to utilise in situ hybridisation and immunocytochemical techniques, although to date it has proven very difficult to demonstrate the presence of either peptide or mRNA transcripts of other known cytokines in normal bone marrow or longer-term marrow cultures. If SCI/MIP-la is also expressed during embryogenesis it is as yet undetectable by in situ hybridisation analyses (N.
Hastie, personal communication), in contrast to TGF-P which is readily detectable in embryonic tissue.
Another approach to elucidate the physiological relevance of a cytokine is by gene inactivation using homologous recombination. However, as SCI/MIP-la is part of a multigene family and there appears to be a redundancy of function between various haemopoietic growth factors, single gene inactivation may not be particularly informative, and cross-breeding of mice with a range of inactivated genes may well provide an exciting approach to the problem. Alternatively, studies on the tissue distribution of the SCI/MIP-la receptor would provide invaluable information on the physiological role of the cytokine, but the biochemical properties of the purified peptide is currently hampering progress in binding studies.
The clinical potential of SCI/MIP-la is obvious. We now have evidence that inoculation of mice with SCI/MIP-li in vivo leads to a dose dependent reduction in the cycling status of CFU-S/CFU-A cells (D. Dunlop, personal communication) . Experiments are now underway in a number of laboratories to evaluate various therapeutic drug protocols.
The possibility that SCI/MIP-la contributes to the suppression of stem cell proliferation in certain neoplasias remains to be explored. In parallel, it would be of significant interest if aberrant SCI/MIP-la gene expression could be linked to specific chromosomal translocations or the activation of certain nuclear proto-oncogene(s). Thus, whilst there are a number of intriguing observations concerning SCI/ MIP-la, a number of detailed studies are required before a clear picture of its physiological role will emerge.
